Discover common skin care ingredients that can cause allergic reactions and learn how to identify them in your products. Chronic idiopathic urticaria, also known as chronic hives or chronic ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Insomnia and other common sleep impacts in CSU improve with biologic medication ...

In patients with chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines, re-treatment with ligelizumab was effective and mostly well tolerated, with both 72-mg and 120-mg doses yielding ...

Enter food therapy—a gentle, empowering approach that harnesses the power of everyday edibles to address root causes like ...

Please provide your email address to receive an email when new articles are posted on . Both guidelines begin with antihistamines. Guidelines in the US recommend further antihistamine use before ...

In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...

Patients with CSU have an elevated risk of anxiety and depression, necessitating comprehensive management strategies. Research is focused on identifying biomarkers and clinical characteristics to ...

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE ...

Please provide your email address to receive an email when new articles are posted on . Urticaria patients taking Dupixent experienced an 8.64-point reduction in itch and 15.86-point reduction in ...

Levels of haptoglobin in serum may help predict which patients with chronic spontaneous urticaria will achieve complete ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...